Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma

Journal of Clinical Oncology

Volumn 23, Issue 15, 2005, Pages 3597-3604

  Chugh, Rashmi ^a   Dunn, Rodney ^a   Zalupski, Mark M ^a   Biermann, J Sybil ^a   Sondak, Vernon K ^a   Mace, Joseph R ^a   Leu, Kirsten M ^a   Chandler, William F ^a   Baker, Laurence H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; RUBITECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHORDOMA; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FIBROSARCOMA; GASTROINTESTINAL STROMAL TUMOR; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; URINARY TRACT INFECTION; VOMITING; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROBABILITY; RISK ASSESSMENT; SARCOMA; SOFT TISSUE TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHORDOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROBABILITY; RISK ASSESSMENT; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20644458342     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.170     Document Type: Article

References (41)

1. Mirra J, Nelson S, Della Rocca C, et al: Chordoma, in Fletcher CD, Unni K, Mertens F (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France, IARC Press, 2002, pp 316-317
2. Pena CE, Horvat BL, Fisher ER: The ultrastructure of chordoma. Am J Clin Pathol 53:544-551, 1970
3. Higinbotham NL, Phillips RF, Farr HW, et al: Chordoma: Thirty-five-year study at Memorial Hospital. Cancer 20:1841-1850, 1967
4. Catton C, O'Sullivan B, Bell R, et al: Chordoma: Long-term follow-up after radical photon irradiation. Radiother Oncol 41:67-72, 1996
5. Chambers PW, Schwinn CP: Chordoma: A clinicopathologic study of metastasis. Am J Clin Pathol 72:765-776, 1979
6. York JE, Kaczaraj A, Abi-Said D, et al: Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 44:74-79, 1999
7. Thilmann C, Schulz-Ertner D, Zabel A, et al: Intensity-modulated radiotherapy of sacral chordoma: A case report and a comparison with stereotactic conformal radiotherapy. Acta Oncol 41:395-399, 2002
8. Fuller DB, Bloom JG: Radiotherapy for chordoma. Int J Radiat Oncol Biol Phys 15:331-339, 1988
9. Debus J, Schulz-Ertner D, Schad L, et al: Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int J Radiat Oncol Biol Phys 47:591-596, 2000
10. Muthukumar N, Kondziolka D, Lunsford LD, et al: Stereotactic radiosurgery for chordoma and chondrosarcoma: Further experiences. Int J Radiat Oncol Biol Phys 41:387-392, 1998
11. Cummings BJ, Hodson DI, Bush RS: Chordoma: The results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys 9:633-642, 1983
12. Hug EB, Loredo LN, Slater JD, et al: Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 91:432-439, 1999
13. Sundaresan N, Galicich JH, Chu FC, et al: Spinal chordomas. J Neurosurg 50:312-319, 1979
14. Demetri GD, Elias AD: Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: Implications for decision making in the clinic. Hematol Oncol Clin North Am 9:765-785, 1995
15. Leu KM, Ostruszka LJ, Shewach D, et al: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22:1706-1712, 2004
16. Kindblom LG, Remotti HE, Aldenborg F, et al: Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269, 1998
17. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998
18. Koh JS, Trent J, Chen L, et al: Gastrointestinal stromal tumors: Overview of pathologic features, molecular biology, and therapy with imatinib mesylate. Histol Histopathol 19:565-574, 2004
19. Garcia-Carbonero R, Supko JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641-661, 2002
20. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989
21. Hertzberg RP, Busby RW, Caranfa MJ, et al: Irreversible trapping of the DNA-topoisomerase I covalent complex: Affinity labeling of the camptothecin binding site. J Biol Chem 265:19287-19295, 1990
22. Kharbanda S, Rubin E, Gunji H, et al: Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 51:6636-6642, 1991
23. Pantazis P, Kozielski AJ, Mendoza JT, et al: Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 53: 863-871, 1993
24. Pantazis P, Early JA, Kozielski AJ, et al: Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: Differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 53:1577-1582, 1993
25. Pantazis P, Hinz HR, Mendoza JT, et al: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52:3980-3987, 1992
26. Natelson EA, Giovanella BC, Verschraegen CF, et al: Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann N Y Acad Sci 803:224-230, 1996
27. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
28. Thall PF, Wathen JK, Bekele BN, et al: Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med 22:763-780, 2003
29. Razis DV, Tsatsaronis A, Kyriazides I, et al: Chordoma of the cervical spine treated with vincristine sulfate. J Med 5:274-277, 1974
30. McSweeney SA, Sholl PR: Metastatic chordoma use of mechlorethamine (nitrogen mustard) in chordoma therapy. AMA Arch Surg 79:152-155, 1959
31. Casali P, Stacchiotti S, Tamborini E, et al: Imatinib mesylate in chordoma. Presented at the 8th Annual Meeting of the Connective Tissue Oncology Society, Barcelona, Spain, November 6-8, 2003
32. Fleming GF, Heimann PS, Stephens JK, et al: Dedifferentiated chordoma: Response to aggressive chemotherapy in two cases. Cancer 72:714-718, 1993
33. Bjornsson J, Wold LE, Ebersold MJ, et al: Chordoma of the mobile spine: A clinicopathologic analysis of 40 patients. Cancer 71:735-740, 1993
34. Chetty R, Levin CV, Kalan MR: Chordoma: A 20-year clinicopathologic review of the experience at Groote Schuur Hospital, Cape Town. J Surg Oncol 46:261-264, 1991
35. Patel SR, Beach J, Papadopoulos N, et al: Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 97:2848-2852, 2003
36. Coggins CA, Elion GB, Houghton PJ, et al: Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 41:485-490, 1998
37. Janss AJ, Cnaan A, Zhao H, et al: Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. Anticancer Drugs 9:641-652, 1998
38. Walterhouse DO, Lyden ER, Breitfeld PP, et al: Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: A Children's Oncology Group study. J Clin Oncol 22:1398-1403, 2004
39. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
40. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
41. Verschraegen CF, Natelson EA, Giovanella BC, et al: A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 9:36-44, 1998